search
Back to results

Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System (MRI-PEM)

Primary Purpose

Breast Cancer

Status
Terminated
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
MRI + PEM image
Sponsored by
Weinberg Medical Physics LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Breast Cancer

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Female over 21 years of age;
  • with a suspicious lesion found in the breast and recommended for biopsy or have a confirmed diagnosis of cancer;
  • and in good health (other than having breast lesions);
  • and can lie still in a prone position for 30 minutes in an MRI scanner.

Exclusion Criteria:

  • Pregnancy;
  • unwilling to give informed consent;
  • have implanted prosthetic heart valve,
  • pacemaker,
  • neurostimulator,
  • surgical clips or other metallic implants;
  • have engaged in occupations or received orthodontic work which may have caused lodging of ferromagnetic materials in the body;
  • are claustrophobic;
  • have been allergic to contrast agents;
  • are diabetic;
  • or have a history of kidney disease.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    No Intervention

    Experimental

    Arm Label

    Diagnostic accuracy with MRI alone

    Diagnostic accuracy with MRI + PEM image

    Arm Description

    The MRI of the breast lesion will be examined. Measures of performance accuracy will be evaluated, including diagnostic sensitivity (true positives divided by true positives and false negatives), diagnostic specificity (true negatives divided by true negatives and false positives), and diagnostic accuracy, defined as the number of correct assessments divided by the number of all assessments.

    The combined PEM/MRI image will be examined.

    Outcomes

    Primary Outcome Measures

    Diagnostic accuracy of combination MRI/positron emission mammography (diagnostic accuracy, defined as the number of correct assessments divided by the number of all assessments)
    Patients with benign disease on biopsy may be followed for up to 2 years after imaging

    Secondary Outcome Measures

    Full Information

    First Posted
    April 9, 2015
    Last Updated
    October 5, 2021
    Sponsor
    Weinberg Medical Physics LLC
    Collaborators
    University of California, Irvine
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02426489
    Brief Title
    Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System
    Acronym
    MRI-PEM
    Official Title
    Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2021
    Overall Recruitment Status
    Terminated
    Why Stopped
    Subcontract PI left institution.
    Study Start Date
    July 1, 2015 (Actual)
    Primary Completion Date
    May 8, 2016 (Actual)
    Study Completion Date
    May 8, 2016 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Weinberg Medical Physics LLC
    Collaborators
    University of California, Irvine

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of the study is to assess whether the addition of positron emission mammography will add diagnostic value to magnetic resonance imaging of the breast, in patients with lesions of the breast that are suspicious enough to warrant biopsy, or which have been confirmed as containing cancer cells.
    Detailed Description
    70 eligible subjects will be asked to undergo contrast-enhanced MRI studies of the breast containing the lesion. Subjects will be asked to fast for 6 hours prior to the imaging session. Each subject will be tested for glucose, and if the glucose is not too high, the subject will be injected with a dose of radioactive sugar (fluoro-deoxyglucose) which has been shown in other studies to accumulate in breast cancers. The subject will be asked to sit quietly for 30 minutes and to empty the bladder. The subject will then be asked to be re-examined in the MRI scanner with MRI contrast injection. The examination bed will be moved out of the MRI scanner and detectors of the radioactive sugar will be placed near the breast in order to obtain a positron emission mammogram for a 10-minute period. The subject will then leave the MRI suite.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Breast Cancer

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    Outcomes Assessor
    Allocation
    Non-Randomized
    Enrollment
    1 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Diagnostic accuracy with MRI alone
    Arm Type
    No Intervention
    Arm Description
    The MRI of the breast lesion will be examined. Measures of performance accuracy will be evaluated, including diagnostic sensitivity (true positives divided by true positives and false negatives), diagnostic specificity (true negatives divided by true negatives and false positives), and diagnostic accuracy, defined as the number of correct assessments divided by the number of all assessments.
    Arm Title
    Diagnostic accuracy with MRI + PEM image
    Arm Type
    Experimental
    Arm Description
    The combined PEM/MRI image will be examined.
    Intervention Type
    Device
    Intervention Name(s)
    MRI + PEM image
    Other Intervention Name(s)
    flurodeoxyglucose
    Intervention Description
    Effect of positron emission mammography on diagnostic accuracy
    Primary Outcome Measure Information:
    Title
    Diagnostic accuracy of combination MRI/positron emission mammography (diagnostic accuracy, defined as the number of correct assessments divided by the number of all assessments)
    Description
    Patients with benign disease on biopsy may be followed for up to 2 years after imaging
    Time Frame
    up to 2 years

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    21 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Female over 21 years of age; with a suspicious lesion found in the breast and recommended for biopsy or have a confirmed diagnosis of cancer; and in good health (other than having breast lesions); and can lie still in a prone position for 30 minutes in an MRI scanner. Exclusion Criteria: Pregnancy; unwilling to give informed consent; have implanted prosthetic heart valve, pacemaker, neurostimulator, surgical clips or other metallic implants; have engaged in occupations or received orthodontic work which may have caused lodging of ferromagnetic materials in the body; are claustrophobic; have been allergic to contrast agents; are diabetic; or have a history of kidney disease.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Irving Weinberg, MD PhD
    Organizational Affiliation
    Weinberg Medical Physics LLC
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System

    We'll reach out to this number within 24 hrs